CMO Hans Eriksson highlights FundaMental Pharma's innovative approach to restoring neuroplasticity in treatment-resistant depression and its potential to address significant unmet patient need.
Read More
Technology Networks – Investigational Drug Could Provide At-Home Treatment-Resistant Depression Care
CMO Hans Eriksson discusses the challenges of developing new treatments for treatment-resistant depression and the potential of dual-acting NMDA receptor modulation to address current gaps…
Read More
Reflections on key discussions from Anglonordic Life Science 2026, including biotech investment trends and the importance of execution in today's market.
Read More
A conversation covering treatment-resistant depression, current challenges in drug development, and the science behind FundaMental Pharma's research.
Read More
An interview exploring the unmet need in treatment-resistant depression and FundaMental Pharma's approach to developing next-generation therapies for patients.
Read More
Industry experts at BioEurope Spring 2026 discuss the future of neuropsychiatric and neurodegenerative diseases drug development and how new technologies and biomarkers could help improve…
Read More
As part of Brain Awareness Week, FundaMental Pharma’s CEO Dirk Beher discussed the potential of clinically validated pathways to address treatment-resistant depression.
Read More
A discussion on the potential of NMDA receptor modulation in depression research and emerging strategies for targeting this key pathway.
Read More
Exploring the role of neuroplasticity in brain disorders and its potential to unlock new therapeutic approaches for patients with CNS diseases.
Read More
CEO Dirk Beher discusses FundaMental Pharma's fundraising journey, the company's financing strategy, and lessons learned for emerging neuroscience companies.
Read More
